Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

CXCL9 (Chemokine (C-X-C motif) ligand 9)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

myPath Melanoma

myPath Melanoma

›

CXCL9 expression	Renal Cell Carcinoma	CXCL9 expression	Renal Cell Carcinoma	lenvatinib Sensitive: C3 – Early Trials lenvatinib Sensitive : C3	lenvatinib Sensitive: C3 – Early Trials lenvatinib Sensitive : C3
IFNG 4-genes signature	Non Small Cell Lung Cancer	IFNG 4-genes signature	Non Small Cell Lung Cancer	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3
IFNG 4-genes signature	Urothelial Cancer	IFNG 4-genes signature	Urothelial Cancer	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3
CXCL9 elevation	Endometrial Cancer	CXCL9 elevation	Endometrial Cancer	pembrolizumab + lenvatinib Sensitive: C3 – Early Trials pembrolizumab + lenvatinib Sensitive : C3	pembrolizumab + lenvatinib Sensitive: C3 – Early Trials pembrolizumab + lenvatinib Sensitive : C3
CXCL9 overexpression	Squamous Cell Carcinoma of Head and Neck	CXCL9 overexpression	Squamous Cell Carcinoma of Head and Neck	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
CXCL9 expression	Urothelial Cancer	CXCL9 expression	Urothelial Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
CXCL9 overexpression	Ovarian Cancer	CXCL9 overexpression	Ovarian Cancer	PD-L1 inhibitor Sensitive: D – Preclinical PD-L1 inhibitor Sensitive : D	PD-L1 inhibitor Sensitive: D – Preclinical PD-L1 inhibitor Sensitive : D